July 9th Webinar: Best of SWOG at ASCO 2025
June typically contains ASCO, Juneteenth, the summer solstice, and our Best of SWOG at ASCO webinar. This year, though, our Best of SWOG event is just a bit later – Wednesday, July 9th, 12-1 pm PT / 3-4 pm ET.
SWOG members should have recently received an email invitation to register for the webinar. Or you can register here.
As in previous years, our 2025 edition of Best of SWOG at ASCO will feature five brief (8 minutes, give or take) presentations of some of the key SWOG results that were delivered at the most recent ASCO Annual Meeting. After each talk, you’ll have a few minutes to pose your questions directly to the presenters (“directly” = via the Chat function – this is 2025).
If you're curious about the format, or about SWOG’s work at last year's ASCO, here's a recording of the 2024 Best of SWOG at ASCO webinar.
For me, this webinar is a don’t-miss event (nitpickers may counter I did miss last June’s webinar, but in my defense, I had been invited to the White House). I encourage you to make it your won’t miss event.
Here are our topics and presenters:
- Konstantin Dragnev, MD, co-chair of S2302 Pragmatica-Lung, will present results from this phase III study in patients with advanced non-small cell lung cancer. Results for the primary endpoint are only the start – we’ve learned (and continue to learn) an enormous amount from this trial.
- Zeynep Eroglu, MD, will present on the results of the randomized phase II S2000, which compared the triplet of encorafenib, binimetinib, and nivolumab to an ipilimumab plus nivolumab combination in patients with BRAFV600-mutant melanoma brain metastases.
- Robert Krouse, MD, will discuss the prevalence of depression, and its association with other baseline variables, in people with advanced prostate cancer, based on an analysis of more than 4,000 participants in SWOG prostate trials.
- Shane Stecklein, MD, PhD, will present work that used samples and data from the SWOG S1416 trial in metastatic triple-negative breast cancer to evaluate the concordance between assessment of homologous recombination deficiency based on tumor tissue and assessment based on circulating tumor DNA.
- Megan Daly, MD, study chair of SWOG S1914, will discuss early results and ongoing work from that trial, the first reported phase III trial to test adding immunotherapy to standard-of-care stereotactic body radiation therapy in patients with high-risk early-stage non-small cell lung cancer.
To attend, simply register via WebEx (name and email are the only required fields), and you’ll be emailed a calendar invitation. See you on the 9th!
Other Recent Stories
